Industry News
Potential Gene Therapy Approach To Sickle Cell Disease
Dec 14, 2012
Researchers at Dana-Farber/Children's Hospital Cancer Center (DF/CHCC) have taken the first preliminary steps toward developing a form of gene therapy for sickle cell disease. In an abstract presented at the 54th annual meeting of the American Society of Hematology, the research team - led by DF/CHCC's Raffaele Renella, MD, PhD, Stuart H. Orkin, MD, and David A... Read More
Potential For New Generation Of Anticoagulants And Improving The Fight Against The Spread Of Malaria
Dec 14, 2012
An international project lead by the Molecular and Cell Biology Institute of Porto University with the participation of researchers from IMIM (Hospital del Mar Medical Research Institute) has, for the first time ever, deciphered the mechanism by which a substance called anophelin binds to an enzyme (thrombin) involved in the process of blood coagulation... Read More
In Melanoma, Suppressive Factors Need To Be Blocked For More Effective Immunotherapy
Dec 14, 2012
Researchers at the Moffitt Cancer Center have found that delayed tumor growth and enhanced survival of mice bearing melanoma were possible by blocking the reconstitution of myeloid-derived suppressor cells and Tregs (suppressors of anti-tumor activity) after total body irradiation had eliminated them... Read More
Predicting Risk In Hodgkin Disease Via Blood Levels Of Immune Protein
Dec 14, 2012
Blood levels of an immunity-related protein, galectin-1, in patients with newly diagnosed Hodgkin lymphoma reflected the extent of their cancer and correlated with other predictors of outcome, scientists reported at the American Society of Hematology annual meeting... Read More
Phase 3 Trial Finds Experimental Graft-Vs.-Host Disease Treatment Equivalent To Standard Care
Dec 14, 2012
An experimental drug combination for preventing graft-versus-host disease (GVHD) was not significantly better than the standard regimen on key endpoints, according to a report of a phase 3 trial at the American Society of Hematology annual meeting... Read More
Boehringer Ingelheim To Initiate Phase III Study In Leukaemia With Its Compound Volasertib* Based On Positive Phase II Results
Dec 13, 2012
New positive Phase II results from an interim analysis of the randomised Phase I/II study involving the company's investigational haematology/oncology compound volasertib* in newly diagnosed patients with acute myeloid leukemia (AML) considered ineligible for intensive remission induction therapy were presented at the 54th American Society of Hematology (ASH) annual meeting in Atlanta, USA... Read More
Elacytarabine In Combination With Idarubicin Shows Promising Efficacy In Phase II Trial In Patients With Early Stage Acute Myeloid Leukaemia (AML)
Dec 13, 2012
Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company, announces data from its Phase II clinical trial with elacytarabine in combination with idarubicin... Read More
For Patients With Aggressive Chronic Lymphocytic Leukemia, Ibrutinib, Rituximab Deliver A 1-2 Punch
Dec 13, 2012
A two-prong approach combining ibrutinib and rituximab (Rituxin®) to treat aggressive chronic lymphocytic leukemia (CLL) produced profound responses with minor side effects in a Phase 2 clinical trial at the University of Texas MD Anderson Cancer Center. Researchers presented the results at the 54th annual meeting of the American Society of Hematology (ASH)... Read More
Children With Very High Risk Form Of Leukemia May Benefit From Intensified Chemotherapy
Dec 13, 2012
Young patients with an aggressive form of leukemia who are likely to relapse after chemotherapy treatment can significantly reduce those odds by receiving additional courses of chemotherapy, suggest the findings of a clinical trial led by investigators at Dana-Farber/Children's Hospital Cancer Center in Boston... Read More
Breast Cancer Survivors More Likely To Develop Diabetes
Dec 13, 2012
Survivors of breast cancer, who are post-menopausal, have a higher chance of developing breast cancer. The new study, published in Diabetologia, is the largest yet to observe this link between surviving breast cancer and eventually developing diabetes; it also showed that whether the patient went on to develop diabetes was closely associated with her having undergone chemotherapy... Read More
Previous Page Next Page